ANANDA DEVELOPMENTS
PLC
("Ananda"
or the "Company")
Result of General
Meeting
Ananda Developments plc (AQSE: ANA),
a life sciences company focused on the research and clinical
development of therapies for a range of complex inflammatory pain
conditions, is pleased to announce that at the General Meeting of
the Company held earlier today, all resolutions were duly passed by
shareholders.
Proxy votes received were as
follows:
|
Resolution No.
|
Resolution Name
|
%
of Votes For
|
%
of Votes Against
|
Total Votes Cast (Excluding Withheld)
|
Number of Votes Withheld
|
|
1 Ordinary
|
To authorise the allotment of
securities as set out in the Notice of General
Meeting
|
99.92%
|
0.08%
|
1,709,794,105
|
266,399
|
|
2 Special
|
To waive pre-emption rights over the
allotment of securities as set out in the Notice of General
Meeting.
|
99.92%
|
0.08%
|
1,709,794,105
|
266,399
|
Accordingly, further to the
announcement of 9 September 2024, the Proposed Debt Capitalisation
as now been approved and a total of 636,309,333 Ordinary Shares
will be issued ("Debt Capitalisation Shares"). Charles Morgan will
receive 632,944,000 Ordinary Shares and will therefore hold
2,428,875,896 Ordinary Shares in the Company, representing 56.40
per cent. of the enlarged share capital. Melissa Sturgess will
receive 3,365,333 Ordinary Shares and will therefore hold
420,367,118 Ordinary Shares in the Company, representing 9.76 per
cent. of the enlarged share capital.
Application to the AQSE Growth Market
Application will be made for the
636,309,333 Debt Capitalisation Shares to be admitted to trading on
Access segment of the AQSE Growth Market. It is expected that
Admission will become effective on 17 October 2024. The Debt
Capitalisation Shares will, on Admission, rank pari passu in all
respects with the Ordinary Shares and will rank in full for any
dividends and other distributions hereafter declared, paid or made
on the ordinary share capital of the Company.
Terms used but not defined in this announcement have the same
meaning as set out in the Company's announcement released at
10.30a.m. on 9 September 2024.
To stay up to date with the latest
developments at Ananda, we encourage you to follow and join our
social media channels which are:
· Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
For
more information please contact:
|
InvestorHub
Engage with us directly at Ananda
Developments Investor Hub
|
Sign up at https://investors.anandadevelopments.com/s/a66906
|
|
ANANDA DEVELOPMENTS PLC
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
|
+44 (0)7463 686 497
ir@anandadevelopments.com
|
|
SP
ANGEL CORPORATE FINANCE LLP
Corporate Finance
Richard Morrison
Caroline Rowe
|
+44 (0)20 3470 0470
|
|
Corporate Broking
Abigail Wayne
Rob Rees
|
|
|
Yellow Jersey PR
Charles Goodwin
Zara McKinlay
|
+44 (0)20 3004 9512
|
About Ananda Developments
Ananda is an AQSE-listed life
sciences company focused on the research and clinical development
of therapies for a range of complex inflammatory pain
conditions.
For further information on the
Company visit https://anandadevelopments.com/
or sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/Wrvx2y